Embolisation of prostate arteries in benign prostatic hyperplasia in non -surgical patients

被引:7
|
作者
Monreal, R. [1 ]
Robles, C. [2 ]
Sanchez-Casado, M. [3 ]
Ciampi, J. J. [1 ]
Lopez-Guerrero, M. [4 ]
Ruiz-Salmeron, R. J. [2 ]
Lanciego, C. [1 ]
机构
[1] Hosp Virgen Salud, Complejo Hosp Univ Toledo, Unidad Radiol Intervencionista, Toledo, Spain
[2] Hosp Univ Virgen Macarena, Serv Endovasc, Seville, Spain
[3] Complejo Hosp Univ Toledo, UCI Bioestadist, Toledo, Spain
[4] Complejo Hosp Univ Toledo, Hosp Virgen Salud, Serv Urol, Toledo, Spain
来源
RADIOLOGIA | 2020年 / 62卷 / 03期
关键词
Prostate; Benign prostatic hyperplasia; Embolisation; Interventional radiology; URINARY-TRACT SYMPTOMS; SINGLE-CENTER; TRANSURETHRAL RESECTION; METAANALYSIS; OBSTRUCTION; PROPOSAL; MODERATE; PAE;
D O I
10.1016/j.rx.2019.07.007
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To present the results of a multidisciplinary study of two tertiary hospitals, together with urology services, on 102 consecutive patients not candidates for surgery treated for more than 6 years, in whom prostatic arteries were embolised for the treatment of benign hyperplasia. Material and methods: From December 2012 to February 2019, 102 patients with symptoms of benign prostatic hyperplasia (BPH) not candidates for surgery or who explicitly rejected surgery, with an average age of 73.9 years (range 47.5-94.5), underwent prostatic artery embolisation. The patients were followed up by questionnaires on urinary symptoms, sexual function and impact on quality of life, as welt as measurement of prostate volume, uroflowmetry and prostate specific antigen (PSA) at one, 3 and 6 months and one year following the procedure. Results: The technique was successful in 96% of patients (76.2% bilateral and 19.8% unilateral). The mean duration of the procedure was 92 minutes and of the radioscopy 35.2 minutes. Statistically significant changes were demonstrated (p <.05) in PSA, peak urinary flow, QoL (quality of life) questionnaire and the International Index of Erectile Function (IPSS). PSA had reduced by 58% from baseline at 3 months. Similarly, the Qmax had increased significantly by 63% in the third month following embolisation. A significant improvement in the QoL and IPSS tests was achieved, with a reduction of 3.7 points and a mean 13.5 points, respectively, at one year's follow-up. Prostate volume showed a non -statistically significant decrease at follow-up of one year following treatment. A series of minor complications was collected, no case of which required hospital admission. Conclusions: Prostatic embolisation for the treatment of BPH proved an effective and safe technique in patients who were not candidates for surgery. 0 2019 SERAM. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 50 条
  • [31] A systematic review of novel surgical treatments for benign prostatic hyperplasia
    Panayi, Zoe
    Musgrave, Hannah
    Adeyoju, Adebanji
    JOURNAL OF CLINICAL UROLOGY, 2025,
  • [32] Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
    Soliman, Mohamed G.
    Al-Ghadeer, Mohammed R.
    Al-Shabaan, Hasan R.
    Al-Hamrani, Amer H.
    AlGhadeer, Hussain Adil
    UROLOGY ANNALS, 2023, 15 (01) : 43 - 47
  • [33] Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review
    Soans, Julian
    Vazirian-Zadeh, Mahmood
    Kum, Francesca
    Dhariwal, Randeep
    Breish, Mohamed Omran
    Singh, Sohail
    Mahmalji, Wasim
    Katmawi-Sabbagh, Samer
    AGING MALE, 2020, 23 (05) : 770 - 779
  • [34] The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume
    Xia, Bo-Wen
    Zhao, Si-Cong
    Chen, Zong-Ping
    Chen, Chao
    Liu, Tian-Shu
    Yang, Fan
    Yan, Yong
    PROSTATE, 2020, 80 (06) : 481 - 490
  • [35] Prospective evaluation of ambulatory laser vaporization of the prostate for benign prostatic hyperplasia
    Berquet, Gaetan
    Corbel, Luc
    Della Negra, Emmanuel
    Huet, Romain
    Trifard, Francois
    Codet, Yann
    Bouliere, Fabien
    Verhoest, Gregory
    Vincendeau, Sebastien
    Bensalah, Karim
    Mathieu, Romain
    LASERS IN SURGERY AND MEDICINE, 2015, 47 (05) : 396 - 402
  • [36] Photoselective vaporization of the prostate in the therapy of benign prostatic hyperplasia
    Kamalov, A. A.
    Osmolovskiy, B. E.
    JOURNAL OF MENS HEALTH, 2008, 5 (02) : 148 - 152
  • [37] Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia
    Lama, John
    Winograd, Joshua
    Codelia-Anjum, Alia
    Bhojani, Naeem
    Elterman, Dean
    Zorn, Kevin C.
    Chughtai, Bilal
    CURRENT UROLOGY REPORTS, 2025, 26 (01)
  • [38] A Preoperative Noninvasive Index Prediction Model for TURP Surgical Outcomes in Patients with Benign Prostatic Hyperplasia
    Yang, Jiyao
    Shi, Hongjin
    Zhan, Hui
    Wang, Haifeng
    Yang, Xiaorong
    Liang, Yuan
    Li, Ji
    Zhang, Qin
    Zhang, Guifu
    Liu, Yidao
    JOURNAL OF INVESTIGATIVE SURGERY, 2025, 38 (01)
  • [39] Systematic review and meta-analysis of prostatic artery embolisation for lower urinary tract symptoms related to benign prostatic hyperplasia
    Pyo, J. -S.
    Cho, W. J.
    CLINICAL RADIOLOGY, 2017, 72 (01) : 16 - 22
  • [40] HoLEP: the new gold standard for surgical treatment of benign prostatic hyperplasia
    Shvero, Asaf
    Calio, Brian
    Humphreys, Mitchell R.
    Das, Akhil K.
    CANADIAN JOURNAL OF UROLOGY, 2021, 28 : 6 - 10